Why the study?
Does prostacyclin modulate platelet-vascular interactions and limit the response to thromboxane A2 in vivo?
Does prostacyclin modulate platelet-vascular interactions and limit the response to thromboxane A2 in vivo?
Prostacyclin modulates platelet-vascular interactions in vivo and limits the response to TxA2, providing a mechanistic explanation for the adverse cardiovascular effects of selective COX-2 inhibitors.
Answers are grounded in this paper and cite their sources.
Animal data link prostacyclin to limiting thromboxane-driven injury; leaves open relevance to COX-2 inhibitor cardiovascular risks in humans.
Thromboxane (Tx) A2 is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA2 formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI2) is a vasodilator that inhibits platelet function. Here we show that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI2 receptor (IP) but are depressed in mice genetically deficient in the TxA2 receptor (TP) or treated with a TP antagonist. The augmented response to vascular injury was abolished in mice deficient in both receptors. Thus, PGI2 modulates platelet-vascular interactions in vivo and specifically limits the response to TxA2. This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), inhibit PGI2 but not TxA2.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: